Business
Vesting and Award of Options under LTIP
Abingdon Health plc announced updates regarding its Long Term Incentive Plan (LTIP), with 16% of FY23 LTIPs vesting based on FY25 revenue and EBITDA targets, resulting in 512,800 options vested at a 7 pence exercise price, while 2,692,199 LTIP shares lapsed. Additionally, new nil-cost LTIPs totaling 3,361,000 shares have been awarded, vesting around October 2028, contingent on achieving FY28 revenue and EBITDA targets. The total outstanding LTIP share options, after accounting for lapsed FY23 options, stand at 10,090,570, representing 3.86% of ordinary shares post-exercise. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n\n \nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\n \nVesting and Award of Options under LTIP\n \nYork, UK 4 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces updates, under the terms of the existing Long Term Incentive Plan established in December 2022 (\"LTIP\" or the \"Plan\"). The Plan issues share options (\"Options\") over ordinary shares of 0.025 pence each (\"Ordinary Shares\") to certain directors and senior management, in order to incentivise and encourage retention in a manner that aligns with the interests of the Company's shareholders.\n \nRegarding the FY23 LTIP, 16% of the LTIPs awarded in December 2022 have now vested against performance criteria for the financial year ended 30 June 2025 (\"FY25\"), based on revenue and EBITDA targets. A total of 512,800 shares with an exercise price of 7 pence have vested as illustrated below, with 2,692,199 LTIP shares from the FY23 scheme lapsing.\n \n\n\n\n\nPDMR\n\n\nRole\n\n\nOptions vested and exercisable under the FY23 LTIP (FY23-FY25 inclusive)\n \n \n\n\nLapsed LTIP under the FY23 LTIP\n\n\n\n\nChris Hand\n\n\nExecutive Chairman\n\n\n68,571\n\n\n360,000\n\n\n\n\nChris Yates\n\n\nChief Commercial Officer President, Abingdon Health USA\n\n\n205,714\n\n\n1,080,000\n\n\n\n\nMark Jones\n\n\nChief Operating Officer\n\n\n96,000\n\n\n504,000\n\n\n\n\nNina Garrett\n\n\nChief Technical Officer\n\n\n82,400\n\n\n432,600\n\n\n\n\nCandice Vendettuoli\n\n\nDirector of QARA\n\n\n45,714\n\n\n240,000\n\n\n\n\nNatalie Thrush\n\n\nChief of Staff/Head of HR\n\n\n14,400\n\n\n75,600\n\n\n\n\n \nIn addition, under the terms of the Plan, the Company has awarded new nil cost LTIPs totalling 3,361,000 shares which will vest circa October 2028, following publication of audited accounts for the financial year ending 30 June 2028 (\"FY28\"), and subject to achieving performance targets based on revenue and EBITDA for performance in FY28. 50% of these new awards are based on achieving revenue targets and 50% are based on EBITDA targets. \n \nNew and existing LTIPs are summarised below:\n \n\n\n\n\nPDMR\n\n\nRole\n\n\...